FDA’s Chief Scientist Has Full Plate To Concentrate On: Clinical Research
This article was originally published in The Tan Sheet
Executive Summary
FDA Chief Scientist Frank Torti will be asked to concentrate on clinical research when he assumes the newly created position in May, the agency says
You may also be interested in...
Von Eschenbach Resigning In January With BTC Debate In His Legacy
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed
People In Brief
FDA's first chief scientist: Frank Torti joins FDA as the agency's chief scientist and principal deputy commissioner, FDA announces April 9. In the newly created position, Torti will help launch the FDA Fellowship Program, an effort to attract as many as 2,000 new professionals to an FDA training program. Despite the absence of congressional funding, the Reagan-Udall Foundation also will be involved in the effort. Torti, whose clinical interests include genitourinary oncology, also will oversee FDA's intramural research programs and emphasize the importance of clinical research trials. He assumes the post in May and is expected to help fill the void in the commissioner's office left by former Chief Medical Officer and Deputy Commissioner Janet Woodcock when she returned to the Center for Drug Evaluation and Research. Torti previously was Director of the Comprehensive Cancer Center at Wake Forest University School of Medicine...
Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects